Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:LOGC

LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

LogicBio Therapeutics logo

About LogicBio Therapeutics Stock (NASDAQ:LOGC)

Key Stats

Today's Range
$6.85
$7.11
50-Day Range
$2.04
$2.07
52-Week Range
$0.26
$3.77
Volume
237,278 shs
Average Volume
303,010 shs
Market Capitalization
$181.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

LogicBio Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
8th Percentile Overall Score

LOGC MarketRank™: 

LogicBio Therapeutics scored higher than 8% of companies evaluated by MarketBeat, and ranked 210th out of 214 stocks in the retail/wholesale sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for LogicBio Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LogicBio Therapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LogicBio Therapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LogicBio Therapeutics has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about LogicBio Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    14.24% of the float of LogicBio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LogicBio Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LogicBio Therapeutics has recently decreased by 0.91%, indicating that investor sentiment is improving.
  • Dividend Yield

    LogicBio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LogicBio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.24% of the float of LogicBio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LogicBio Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LogicBio Therapeutics has recently decreased by 0.91%, indicating that investor sentiment is improving.
  • Search Interest

    3 people have searched for LOGC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of LogicBio Therapeutics is held by insiders.

  • Percentage Held by Institutions

    46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LogicBio Therapeutics' insider trading history.
Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LOGC Stock News Headlines

LGCB Linkage Global Inc
Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
LogicBio Therapeutics, Inc. (LOGC)
RVVTF Revive Therapeutics Ltd.
LogicBio's IPO: What You Need To Know
See More Headlines

LOGC Stock Analysis - Frequently Asked Questions

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Monday, November, 15th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.01. The firm earned $2.12 million during the quarter, compared to analyst estimates of $5.02 million. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 81.98% and a negative net margin of 141.03%.

LogicBio Therapeutics (LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

LogicBio Therapeutics' top institutional shareholders include Barclays PLC (0.18%).
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB).

Company Calendar

Last Earnings
11/15/2021
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/03/2025

Industry, Sector and Symbol

Industry
Catalog & mail-order houses
Sub-Industry
N/A
Current Symbol
NASDAQ:LOGC
Fax
N/A
Employees
62
Year Founded
N/A

Profitability

Net Income
$-317,000,000.00
Net Margins
-141.03%
Pretax Margin
-141.67%

Debt

Sales & Book Value

Annual Sales
$287 million
Book Value
$5.82 per share

Miscellaneous

Free Float
26,185,000
Market Cap
$181.33 million
Optionable
Optionable
Beta
2.05
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:LOGC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners